Blue Owl Capital Holdings LP
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 15, 2024), Blue Owl Capital Holdings LP reported 40 stock positions worth $359.5 million. Its top holding was Cullinan Therapeutics (CGEM) at 9.9% of the portfolio, followed by Pliant Therapeutics (PLRX, 9.0%) and Blue Owl Capital (OBDC, 8.7%). Compared with Q1 2024, it opened 10 new positions, sold out of 14, added to 7 and reduced 8. The biggest buy was a new position in Context Therapeutics (CNTX) and the biggest sale an exit from Robinhood Markets Class A (HOOD).
- Most Recent 13F
- Q2 2026
- Location
- New York, NY
- CIK
- 0001858703
- Portfolio Value
- $359.5M (Q2 2024)
- SEC Filing
- 0000950123-24-008845 ↗ filed Aug 15, 2024
Holdings Value
Holdings 40 stocks · $359.5M
| CGEM Cullinan Therapeutics Inc. | 9.94% | 2,049,172 | $35.7M | Reduce -29.9% |
| PLRX Pliant Therapeutics Inc. | 8.98% | 3,004,199 | $32.3M | No change |
| OBDC Blue Owl Capital Corp. | 8.74% | 2,045,070 | $31.4M | No change |
| KVYO Klaviyo Inc. Class A | 8.30% | 1,198,270 | $29.8M | No change |
| LRMR Larimar Therapeutics Inc. | 7.78% | 3,859,468 | $28.0M | Reduce -3.4% |
| ENGN Engene Holdings Inc. | 6.43% | 2,449,827 | $23.1M | Reduce -0.5% |
| TRML Tourmaline Bio Inc. | 6.14% | 1,715,401 | $22.1M | Add +18.5% |
| EVCM Evercommerce Inc. | 5.01% | 1,641,929 | $18.0M | No change |
| SLRN Acelyrin Inc. | 3.59% | 2,926,028 | $12.9M | Add +3.5% |
| RPTX Repare Therapeutics Inc. | 3.10% | 3,372,499 | $11.1M | Add +8.0% |
| RARE Ultragenyx Pharmaceutical Inc. | 3.07% | 268,238 | $11.0M | No change |
| CNTX Context Therapeutics Inc. | 2.88% | 5,161,290 | $10.3M | New |
| IRON Disc Medicine Inc. | 2.70% | 215,260 | $9.7M | Add +38.6% |
| TOST Toast Inc. Class A | 2.31% | 322,578 | $8.3M | No change |
| ETWO E2OPEN Parent Holdings Inc. | 2.06% | 1,650,943 | $7.4M | No change |
| KROS Keros Therapeutics Inc. | 2.00% | 157,633 | $7.2M | Reduce -8.7% |
| IKENA ONCOLOGY INC | 1.88% | 4,091,118 | $6.8M | Add +5.1% |
| SGMT Sagimet Biosciences Inc. Class A | 1.59% | 1,673,877 | $5.7M | No change |
| MLYS Mineralys Therapeutics Inc. | 1.47% | 450,339 | $5.3M | Reduce -16.8% |
| VKTX Viking Therapeutics Inc. | 1.40% | 95,000 | $5.0M | New |
| INZY Inozyme Pharma Inc. | 1.39% | 1,120,027 | $5.0M | Reduce -11.8% |
| STWD Starwood Property Trust Inc. | 1.19% | 226,456 | $4.3M | New |
| PYXS Pyxis Oncology Inc. | 0.96% | 1,046,025 | $3.5M | New |
| MREO Mereo Biopharma Group PL-ADR | 0.90% | 897,809 | $3.2M | New |
| AQST Aquestive Therapeutics Inc. | 0.82% | 1,140,000 | $3.0M | Add +30.3% |
| CMPX Compass Therapeutics Inc. | 0.79% | 2,829,712 | $2.8M | No change |
| ADCT Adc Therapeutics SA | 0.64% | 733,568 | $2.3M | No change |
| OMGAQ Omega Therapeutics Inc. | 0.61% | 1,055,882 | $2.2M | No change |
| GPCR Structure Therapeutics Inc. | 0.60% | 55,000 | $2.2M | New |
| IMVT Immunovant Inc. | 0.59% | 80,000 | $2.1M | Reduce -20.0% |
| SYRS Syros Pharmaceuticals Inc. | 0.49% | 340,855 | $1.8M | No change |
| JANX Janux Therapeutics Inc. | 0.47% | 40,000 | $1.7M | New |
| CELC Celcuity Inc. | 0.30% | 65,000 | $1.1M | New |
| BLND Blend Labs Inc. Class A | 0.24% | 361,587 | $853K | No change |
| GOCOQ Gohealth Inc. Class A | 0.23% | 83,264 | $815K | No change |
| ENGENE HOLDINGS INC | 0.17% | 51,177 | $608K | Reduce -90.0% |
| PLUM ACQUISITION CORP III | 0.09% | 70,000 | $324K | New |
| DM Desktop Metal Inc. Class A | 0.09% | 750,000 | $310K | Add +900.0% |
| DTIL Precision Biosciences Inc. | 0.05% | 20,220 | $197K | No change |
| GERN Geron Corp. | 0.03% | 23,918 | $101K | New |
Other holdings (1): bonds, preferreds, convertibles and warrants · $47K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| PLMWF Plum Acquisition Corp. III-CW | *W EXP 03/31/202 | 666,666 | $47K | No change |
Total filed on the 13F, all lines: $359.6M.
Portfolio Sells Q1 2024 → Q2 2024
| HOOD Robinhood Markets Inc. Class A | Sold out | 0.00% | −10.78 |
| ENGN Engene Holdings Inc. | Reduce -0.5% | 6.43% | −1.91 |
| MLTX Moonlake Immunotherapeutics | Sold out | 0.00% | −1.00 |
| DELL Dell Technologies -C | Sold out | 0.00% | −0.94 |
| DIREXION SHS ETF TR | Sold out | 0.00% | −0.71 |
| MDGL Madrigal Pharmaceuticals Inc. | Sold out | 0.00% | −0.71 |
| BDTX Black Diamond Therapeutics I | Sold out | 0.00% | −0.70 |
| INZY Inozyme Pharma Inc. | Reduce -11.8% | 1.39% | −0.55 |
| OVID Ovid Therapeutics Inc. | Sold out | 0.00% | −0.53 |
| BRZE Braze Inc. Class A | Sold out | 0.00% | −0.47 |
| ENGENE HOLDINGS INC | Reduce -90.0% | 0.17% | −0.36 |
| KROS Keros Therapeutics Inc. | Reduce -8.7% | 2.00% | −0.28 |
| SNOW Snowflake Inc. | Sold out | 0.00% | −0.25 |
| GTLB Gitlab Inc. Class A | Sold out | 0.00% | −0.24 |
| RLYB Rallybio Corp. | Sold out | 0.00% | −0.13 |
| ELVN Enliven Therapeutics Inc. | Sold out | 0.00% | −0.09 |
| IMVT Immunovant Inc. | Reduce -20.0% | 0.59% | −0.06 |
| FATHOM DIGITAL MFG CORP | Sold out | 0.00% | −0.05 |
| CGEM Cullinan Therapeutics Inc. | Reduce -29.9% | 9.94% | −0.02 |
| UBER Uber Technologies Inc. | Sold out | 0.00% | −0.02 |
| MLYS Mineralys Therapeutics Inc. | Reduce -16.8% | 1.47% | +0.07 |
| LRMR Larimar Therapeutics Inc. | Reduce -3.4% | 7.78% | +1.73 |
Portfolio Buys Q1 2024 → Q2 2024
| CNTX Context Therapeutics Inc. | New | 2.88% | +2.88 |
| VKTX Viking Therapeutics Inc. | New | 1.40% | +1.40 |
| STWD Starwood Property Trust Inc. | New | 1.19% | +1.19 |
| PYXS Pyxis Oncology Inc. | New | 0.96% | +0.96 |
| MREO Mereo Biopharma Group PL-ADR | New | 0.90% | +0.90 |
| IKENA ONCOLOGY INC | Add +5.1% | 1.88% | +0.77 |
| IRON Disc Medicine Inc. | Add +38.6% | 2.70% | +0.77 |
| GPCR Structure Therapeutics Inc. | New | 0.60% | +0.60 |
| JANX Janux Therapeutics Inc. | New | 0.47% | +0.47 |
| CELC Celcuity Inc. | New | 0.30% | +0.30 |
| RPTX Repare Therapeutics Inc. | Add +8.0% | 3.10% | +0.16 |
| PLUM ACQUISITION CORP III | New | 0.09% | +0.09 |
| AQST Aquestive Therapeutics Inc. | Add +30.3% | 0.82% | +0.08 |
| GERN Geron Corp. | New | 0.03% | +0.03 |
| DM Desktop Metal Inc. Class A | Add +900.0% | 0.09% | −0.05 |
| SLRN Acelyrin Inc. | Add +3.5% | 3.59% | −0.22 |
| TRML Tourmaline Bio Inc. | Add +18.5% | 6.14% | −0.26 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 48 | $656.7M | SPCX, AKTS, CGEM, LRMR, NCDL |
| Q1 2026 | 54 | $369.9M | AKTS, LRMR, ENGN, NCDL, CGEM |
| Q4 2025Amended | 50 | $320.9M | ENGN, NCDL, OBDC, LRMR, CGEM |
| Q3 2025 | 46 | $319.9M | NCDL, OBDC, ENGN, LRMR, EVCM |
| Q2 2025 | 46 | $308.2M | NCDL, OBDC, CGEM, EVCM, TRML |
| Q1 2025 | 45 | $309.2M | NCDL, OBDC, CGEM, EVCM, TRML |
| Q4 2024 | 48 | $432.6M | NCDL, KVYO, PLRX, OBDC, CGEM |
| Q3 2024 | 68 | $514.6M | NCDL, KVYO, TRML, PLRX, CGEM |
| Q2 2024 | 40 | $359.5M | CGEM, PLRX, OBDC, KVYO, LRMR |
| Q1 2024 | 44 | $500.6M | HOOD, CGEM, PLRX, ENGN, TRML |